Prevention of recurrent depressive episodes with milnacipran: Consequences on quality of life

Journal of Affective Disorders

Volumn 58, Issue 3, 2000, Pages 171-180

  Rouillon, F ^a   Berdeaux, G ^b   Bisserbe, J C ^b   Warner, B ^b   Mesbah, M ^c   Smadja, C ^b   Chwalow, J ^d  

^a HÔPITAL LOUIS MOURIER   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^c Laboratoire Sabres Rue Yves Mainguy   (France)

^d INSERM   (France)

Author keywords

Depression; Prevention; Quality of life; Recurrence

Indexed keywords

MILNACIPRAN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CYCLOPROPANES; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; RECURRENCE; TREATMENT OUTCOME;

EID: 0034098521     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0327(99)00109-3     Document Type: Article

References (30)

1. Akiskal H.S. Mood disorders: introduction and overview. Kaplan H.I., Saddock B.J. Comprehensive Textbook of Psychiatry. 6th ed :1995;1067-1078 Williams and Wilkins, Baltimore.
2. Angst J. Montgomery S.A., Rouillon F. How Recurrent and Predictable is Depressive Illness' in Long-term Treatment of Depression. 1992;1-13 John Wiley & Son.
3. Barge-Schaapveld D.Q.C.M., Nicolson N.A., van der Hoop R.G., DeVries M.W. Changes in life experience associated with clinical improvement in depression. J. Affect. Disord. 34:1995;139-154.
4. Baudoin C., Fardellone P., Thelot B., Juvin R., Potard V., Bean K., Sebert J.L. Hip fractures in France: The magnitude and perspective of the problem. Osteoporosis Int. 3:(Suppl. 3):1996;S1-S10.
5. Baudoin C., Fardellone P., Bean K., Ostertagezembe A., Hervy F. Clinical outcomes and mortality after hip fracture a 2-year follow-up study. Bone. 18:(Suppl. 3):1996;149S-157S.
6. Brion S., Audrain S., de Bodinat C. Episodes dépressifs majeurs de sujets âgés de plus de 70 ans: évaluation de l'efficacité et de l'acceptabilité de la tianeptine et de la mianserin. La Presse Médicale. 25:1996;461-468.
7. Chwalow, A.J., Lurie, A., Bean, K., du Chatelet, I.P., Venot, A., Dusser, D., Douot, Y., Strauch, G., 1992. A French version of the Sickness impact Profile (SIP): stages in the cross cultural validation of a generic quality of life scale. Fundam. Clin. Pharmacol. 319-326.
8. Chwalow, J., Mesbah, M., Hamon, A., Berdeaux, G., 1998. Validation of a French quality of life instrument for patients with repeated episodes of clinical depression: a truncated version of the French Sickness Impact Profile [abstract], Quality of Life Research, in press.
9. Cox D.R., Oakes D. Analysis of Survival Data. 1984;Chapman and Hall, London.
10. Damiano A.M. The sickness impact profile. Spilker B. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed :1966;Lippincott-Raven Publisher, Philadelphia.
11. Diagnostic and Statistical Manual, 4th ed. American Psychiatric Press, Washington DC, 1994; 339-345.
12. Fleming T., Harrington D. Counting Processes and Survival Analysis. 1991;John Wiley and Son, New York.
13. Goethe J.W., Fisher E.H. Functional impairment in depressed inpatients. J. Affect. Disord. 33:1995;23-29.
14. Guy, W., 1976. ECDEU-Assessment manual for Psychopharmacology. National Institute of Mental Health (Ed.). ECDEU Assessment manual for psychopharmacology, US Department of Health Education and Welfare 1976.
15. Hamilton M. A rating scale for depression. J Neurol. Neurosurg. Psychiatry. 23:1960;56-62.
16. Hirschfeld R.M.A. Psychosocial predictors of outcome in depression. Bloom F.E., Kupfer D.J. Psychopharmacology: the Fourth Generation of Progress. 1994;1113-1122 Raven Press, New York.
17. Keller, M.B., Lavori, P., Mueller, T., Endicott, J., Coryell, W., Hirschfelf, R., Shea, T., 1992. Time to recovery, chronicity, and levels of psychopathology in major depression. Arch. Gen. Psychiatry 49.
18. Kraemer H.C. Methodological and statistical progress in psychiatric clinical research: a statistician's perspective. Bloom F.E., Kupfer D.J. Psychopharmacology: the Fourth Generation of Progress. 1994;1849-1860 Raven Press, New York.
19. Lonnqvist J., Sihvo S., Syvâlahti E., Sintonen H., Kiviruusu O., Pitkanen H. Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine. Acta Psychiatr. Scand. 89:1994;363-369.
20. Lonnqvist J., Sihvo S., Syvâlahti E., Sintonen H., Kiviruusu O., Pitkanen H. Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression. Acta Psychiatr. Scand. 91:1995;189-194.
21. Mezzich J.E. International perspectives on psychiatric diagnosis. Kaplan H.I., Saddock B.J. Comprehensive Textbook of Psychiatry. 6th ed :1995;692-704 Williams and Wilkins, Baltimore.
22. Revicki D.A., Turner R., Brown R., Martindale J.J. Reliability and validity of a health-related quality of life battery for evaluating outpatient antidepressant treatment. Quality Life Res. 1:1992;257-266.
23. Rouillon, F., Warner, B., Pezous, N., Bisserbe, J.-C., and the milnacipran study group. Milnacipran efficacy in the prevention of recurrent depression: a 12-month study. Int. Clin. Psychopharmacol. (in press).
24. Stoker M.J., Dunbar G.C., Beaumont G. The Smith-Kline 'quality of life' scale: a validation and reliability study in patients with affective disorder. Quality Life Res. 1:1992;385-395.
25. Surtess P., Barkley C. Future Imperfect: the long term outcome of depression. Br. J. Psychiatry. 164:1994;327-341.
26. Turner R. Quality of life: experience with sertraline. Int. Clin. Psychopharmacol. 9:(Suppl. 3):1994;27-31.
27. Walker V., Streiner D.L., Novosel S., Rocchi A., Levine M.A.H., Dean D.M. Health-related quality of life in patients with major depression who are treated with moclobemide. J. Clin. Psychopharmacol. 15:(Suppl 2):1995;60S-67S.
28. Wells K.B., Stewart A., Hays R.D., Rogers W., et al. The functioning and well-being of depressed patients: results from the medical outcomes study. J. Am. Med Assoc. 262:(7):1989;914-919.
29. Weinstein M.-C. Costs of prevention. J. Gen. Intern. Med. 5:(Suppl.):1990;S89-92.
30. Zimmerman M., Coryell M., Corenthal C., Wilson S.O. A self-reported scale to diagnose major depressive disorder. Q. Arch. Gen. Psychiatry. 43:1986;1076-1081.